Randomized Phase Ii/Iii Study Of Standard R-Chop Versus Chop Combined With Dose-Dense Weekly Rituximab (Rw-Chop) For Previously Untreated Dlbcl: Jcog0601
BLOOD(2018)
Abstract
Background: CHOP plus rituximab (R-CHOP) is the standard of care for previously untreated DLBCL. R-CHOP comprises CHOP and one-dose rituximab in each 21-day cycle; however, the schedule of rituximab administration has not been fully optimized. Dose-dense rituximab was expected to increase its peak concentration to enhance the synergistic effect with chemotherapy at early phase of treatment. To compare weekly administration of rituximab combined with CHOP (RW-CHOP) with standard R-CHOP in patients with previously untreated DLBCL, we conducted a multicenter, randomized phase II/III study (JCOG0601, UMIN000000929).
MoreTranslated text
Key words
CHOP,Rituximab,Diffuse large B-cell lymphoma,Vincristine,Chemotherapy regimen,Neutropenia,Cyclophosphamide,Prednisone,Oncology,Medicine,Internal medicine
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined